DOCSLIB.ORG

Rd Edition, ‘ Revised and Enlaqgei)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rd Edition, ‘ Revised and Enlaqgei) \~. THIRD EDITION, ‘ REVISED AND ENLAQGEI). ‘lr . ' DOSE BOOK} REFERENCE TABLES, FOR PHYSICIANS AND PHARMACISTS. Price, 50 cents, postpald. D. o; HAYNES & to, Publishers NEW YORK. -.( TABLE OF CONTENTS. 13’ f3; ' TI—IIRD EDITION, REVISED AND ENLARGED. li‘ I ‘ PAGES 1. DOSE LIST. ......u...... H017 ' This llst gives the doses of some 2600 remedies. including all the Newer Remedies to date and all preparations111 the Pharmacopcelas of the United States. Great Britain and Germany. also all National Formulary preparations. 2. PROPERTIES OF REMEDIAL AGENTS. ....... ....... 17I0v18 ‘ A glossary giving short definitions of , e .. ical propertiesof remedies used in medicine.terms employed to designate the med ‘ '-—<~—\..~.-~—_. E 3 VETERINARY DOSES ..... .. ..... ..... .......... ... ... I9to 23 ' IA posological table of all the i with doses for Horses, Cattle.prominentSheep, Swineremediesand Dogs.used1nveterinary Iiractice E 4..INCOMPATIBLES.. ..... ..... ..... .. ......... .............. 2310 24 -‘ A list of the more important incompatibles Chemical Pharmaceutical and Physiological.arranged in three divisions viz.: .-5. POISONS AND THEIR ANTIDOTES. ....... .......... 24 I0 25 " ' The poisons classified forarequickarranged'reference.in groups with antidotes for each group clearly ' 6i TABLE OF SOLUBILITIES..... .... .. ..... 26h) 33 Showing the solubilities of some 500 different medical substances1n water ‘34:.1‘." alcohol, ether chloroform and glycerin. if" 7'. LATIN WORDS AND PHRASES.. .. ... 34 to 38 t" A list of Latin words and phrases used in prescription writing, with their I, 3 '' ,‘ ."conesponding contractions and English equlvalents . E ‘1 8 TERMS OCCURRING IN FRENCH AND GERMAN PRESCRIPTION8:. 3,9 to 40 fit: tAonsmost complete list of words employed in . " 10 French and German prescrip- ‘j',9. DROPS IN A FLUIDRAM.. .... ........ 4110 42 I; ‘ . A table showing the number of drops in a fluidram with i1, :1 p _ Weight1n grains and grams, for each preparation named. corresponding \ If {19. SPECIFIC GRAVITIES OF OFFICIAL SUBSTANCES... '..........................page 43 .3. - This Ist includes all substances whose specific f . _ . Pharmacopoeia. gravities are mentioned in the 11.. THE METRIC SYSTEM” .. ... .. .............. 441a 4‘5 7 Complete tables Showing the equivalents of ‘ relation of tioy. weightstometa1c, etc. etc. ayoirdupois weight in grams, . -.AVA.a),.17... .1. 12'. TABLE OF PERCENTAGE SOLUTIONS. ................... .page 46' . A table of the morecommon percentage forsuiticient distiled water to make 1 pint.solutions. calculated approximately "“13." TABLE or THERMOMETRIC EQUIVALENTS. ..... ... ..page .46 Fahrenheit and Centigradescales. with instructions for reducing Centi- grade degrees to thoseof Fahrenheit and vice versa. .' roosE EQUIVALENTS. ... .' . ........ .. -3d‘Cover. This table shows at a glance the amount of drug contained1n each teaspoon -fu_I ofany mixturefrom 1 ounce to a quart. COMPILED AND ARRANGED ESPECIALLY FOR USE IN I WRITING ,AIII] IDISPEIISIIIE 'PIIESIIBIPTIOIIS. ” COMPRISING A LIST, WITH DOSES, OF ALL REMEDIES OFFICIAL IN THE PHARMA- :1 I > COPCEIAS OF THE UNITED STATES, GREAT BRITAIN AND GERMANY, AND I I ALSO THOSE OF THE NATIONAL FORMULARY (REVISED EDITION), TO WHICH HAVE BEEN ADDED MANY STANDARD PREPARATIONS, NEW REMEDIES, SYNTHETIC COMPOUNDS, ETC., A POSOLOGICAL TABLE OF THE MORE IMPORTANT REMEDIES USED _ U IN VETERINARY PRACTICE, ALSO A VAL- UABLE COIJLECTION OF REFERENCE TABLES; n_g;w. COMPILED BY THE PHARMACEUTICAL ERA. u THIRD EDITION. Alum-1......v.-.. REVISED AND ENLARGED. ‘ A NEW YORK: D. 0. HAYNES & COMPANY, PUBLISHERS. _,._.._4-__ .-...__.-u-- M . I-“n. .1. .-.«..-: -I. _ 4- «.» L. 4;-‘n«l -74. “7.. «r .—“w m. -»-e._" .d “nun: ”a: A. DOSE LIST DRUGS,CHEHICALS AND PHARMACEUTICALS. Prepared Especially for Reference in Dispensing. In this list are Included all remedies official In the Pharmacopceias of the United States, Great Britain and Germany, also, all preparations contained in the National Formulary, and many others, including New Remedies, Synthetic Compounds, Etc. COMPILED FROM STANDARD MEDICAL AND PHARMACEUTICAL LITERATURE. THE DOSES GlVEN ARE FOR ADULTS. The following rules will serve to proportion the dose according tothe age of the patient: dose to be . .. .. .. 1 or 1 drachm (60 grains). For an adult, suppose the .. .... .. 1-12 :‘ 5 grains. A child ‘under % year‘would require ..............}§ ‘ 8grains. 3 “ “ ...... 1-6 “ 10 grains. “ 4 " “ “ 15grains. “ 7 “ “ “ lscru le. “ 14 “ “ “ drac m. “ 20 “ “ % “ scru lee. From20to 60years,thefull dose............ ..... 1 “ 1drsc . Above 60 years an inverse gradation should beobserved. Doses FOR CHILDREN—YOUNG’S RULE—Add 12 to the age and divide by the use. Use the as the denominator ot!_ a. fraction whose numerator is 1. This fraction w 1 represent uotient compared With that for an adult. Example—For a child two years old: t e size of dose The dose is 1-7of that for an adul . 2+12==14. Divide by 2=7. Pharmacopoeia. Anennvunous: U.lain—BritishS.—UnitedPharmacopoeia.States Pharmacopoeia. Gen—GermanN. F.—Nutional Formulsry. gr. Abrastol ........... .......... 15 to 30 gr. Acldum Anticylicum . ..1-250 toto1-10111 gr. Abroma Augustum ............. 20 to 30 gr. Arsenosum—U. S.,S., Br.,Br., Ger...Ger. .1-6010 to 30 gr. Absinthium—U. S., Ger.......... 20 to 40 gr. Benzoicum—U.Borlcum—U. S., Gen, Br. 10 to ‘30 gr. Abstractum Aconiti ............ V4, to 201/2 gr. Borocitricum . .............. 5 ‘to 20 gr. Aspidospermee .............. 5 to 11/2 gr. Caincic ..... ............... 2 to 15 gr. Belladonna: ............................. 1,421 to 3 gr. Camphorlcum 15 to 30 gr. CannabisConil ......................Indies: 1 to 2 gr. Carbollcum—U. S., Br., Ger. 1 to 3 gr. Digitalis ................... 1 to 3 gr. Carbolicum Liquefactum—Br., min. Gelsemii 1 to 2 gr. Ger...... ........... 41 to 46 gr. Hyoscyami ................ to 5 gr. Cathartinicum ...............S., Br., Ger. .1-24 to 1/1. gr. Ignatiae .................... 1 to 3 gr. Citricum—U.Chromicum—U.S., Br., Ger. 10 to 30 gr. Ipecacuanhae .............. 63 to 1030 gr. Cubeblcum .............. 2 to 10 gr. JalapseNucis Vomicee.................................. 1A, to 1A; gr. Dlthiosalicylicum 2 to 3 gr. —._.—.M._.1-At Phytolaccae 5 to 15 gr. Embelicum ............ 3 to 206 mingr. Pilocarpi ................... 6 to 30 gr. Fluoricum Dilutum . 10 5 min. Podophylli .................. 2 to 5 gr. Formicum—Ger.Gallicum—U. S., .....Br. 5 to 30 gr. Senegae .................... 5 to 1510 gr. Gynocardicum ............... 1,§ to 3 gr. Valerianae ................................ 101 to 2 gr. Hippuricum ................ 4 to 15 gr, AcetalVeratri. ......................Viridi 1 to dr. Hydrobromicum Dilutum—U. Acetanilldum—U. S., Br., Ger... 3 to 15 gr. S., r................... 1,9 to 2 fl.dr.. Aceton ......................... 5 to 10 min, Hydrochloricum—U. S., Br., 5 to 10 min. 11.. Acetparatoluld ................. 10 to 30 gr. HydrochloricumGer ......................Dilutum—U. _ Acetum—U. S. 1 t0 4 fl.dl‘. S., Br., Ger.............. 10 to 30 min. Acetum Digitalis—Ger----------- 10 to 4060 min. Hydrocinnamicum. See Acidv ' Ipecacuanhae—Br.......................... 1/4,5 to 2 dr. um Phenylypropionicum. ' ."~. Lobellee—N.Opii—U. S: ..................F. 5 to 15 min. Hydrocyanicum Dilutum—U. .Sanguinaria—N. F. ......... 5 to 60 min. ., r................... 1 to 3fl.ozs.min. an; Scmae-U. S., Br., Ger....... 10 to 30 min. Hydrosnlphuricum Dilutum—.......... 2 to 4 Acetylphenyhydrazin . ...... 374, to 374 gr. Hypophosphorosum...... ......... 10 to 60 min. Acidum Aceticum Dilutum~U. 2 to 4 fl.dr. IodicumU. S . ............... 1 to 4 gr. 5;, Br., Ger.............. gr. ' Lactlcum—U. S., Br., Ger... 1/; to 2 fl.dr. Agsricum -------------------........ 1-31 toto 1%3 gr. Lactlcum Dilutum—B. F. 17$ to 2 fl.dr. AlphatoluicumAnlslcum tonnnurnnnvn. 5t015gr. LRTTCiCum y'ovv'unnnneul'lzt01'6‘1‘0 THE ERA DOSE BOOK. Di- Ammonii Boras ................ 4gr. Acidum t.um—NMetaphosphoricumF.............. 1/2 to 1 fl.dr. Camphorata .. ........ 1 to 3 gr. Nitricumlut Dilutum—U. Si, Br. 5 to 30 mm. Carbolas . ................ 2 to 6 gr. Nitrohydrochloricum—U S. .. 2 to 5 min. Carbonas—U...................S. Br.., Ger. 1/85 to 151%gr.g1. Nitrohydrochloricum Dilutum CarbozoasChloridum—U. S., Br., Ger. 5 to 30 gr. —U. S., ............... 10 to 20 gr.min. Embellcum 1-30 to 1-15 gr. Orthoamldo.................Sallcylicum....... 1/23 to 17 gr Fluorldum ............... .1-24 to 1,4 gr. OxalicumParacresotlcum ........... to 20 gr Formas ..................... 3 to 5 gr. Perosmlcum .................1-16 to 34 gr. HyposulphisHypophosphis............................... 5 to 30 gr Phenylaceticum .............. 1 to 3 gr. Iodidum—U. S. ............. 3 to 10 gr. Phenylpropionlcum—— U. .........S., Br., Nitras—U. S., Br............ 10 to 30 gr. PhosphoricumGer ................. 3 to 7 min. Phosphas—Br. ............... 5 to 20 gr. Phosphoricum Dilutum — U. SallcylasPicras .......................................... 142 to 201 gr.gr S., Br. ............. 5toto 302 gr.min. Succinas ........ ........... 1 to 4 gr Picricum ............ .. 3/414 to 1 gr. Sulphas ..................... 5 to 20 gr PolygallicumPyrogallicum. ........See Pyrogallol. Sulphis ..................... 5 to 20 gr Salicylicum—U. S., Br., Ger.. 10 to 25 gr. Sulphocarbolas .............. 1 to 5 gr Sclerotlcum . to 1 Sulphoichthyolas.T :hyol. See Ich- SulphanilicumSuccinicum arras ................. 51:030 r. Sulphurlcum Aromaticum—U. min AmpelopsinValerianas—U. S. 2 to 8 gr. S., B. ......... 5 to
Load more

Recommended publications
  • Treatment Repurposing for Inflammatory Bowel Disease Using Literature-Related Discovery and Innovation Kostoff RN, Briggs MB, Shores DR
    ISSN 1007-9327 (print) ISSN 2219-2840 (online) World Journal of Gastroenterology World J Gastroenterol 2020 September 7; 26(33): 4889-5059 Published by Baishideng Publishing Group Inc World Journal of W J G Gastroenterology Contents Weekly Volume 26 Number 33 September 7, 2020 FRONTIER 4889 Treatment repurposing for inflammatory bowel disease using literature-related discovery and innovation Kostoff RN, Briggs MB, Shores DR REVIEW 4900 Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells Polidoro MA, Mikulak J, Cazzetta V, Lleo A, Mavilio D, Torzilli G, Donadon M MINIREVIEWS 4919 Exploring the food-gut axis in immunotherapy response of cancer patients Russo E, Nannini G, Dinu M, Pagliai G, Sofi F, Amedei A ORIGINAL ARTICLE Basic Study 4933 Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice Bluemel S, Wang Y, Lee S, Schnabl B 4945 Resveratrol alleviates intestinal mucosal barrier dysfunction in dextran sulfate sodium-induced colitis mice by enhancing autophagy Pan HH, Zhou XX, Ma YY, Pan WS, Zhao F, Yu MS, Liu JQ Retrospective Study 4960 Effects of denosumab treatment in chronic liver disease patients with osteoporosis Saeki C, Saito M, Oikawa T, Nakano M, Torisu Y, Saruta M, Tsubota A 4972 Bowel function and quality of life after minimally invasive colectomy with D3 lymphadenectomy for right- sided colon adenocarcinoma Lee KM, Baek SJ, Kwak JM, Kim J, Kim SH 4983 Acute liver failure and death
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0165636A1 Hasebe Et Al
    US 2006O165636A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0165636A1 HaSebe et al. (43) Pub. Date: Jul. 27, 2006 (54) HAIR TREATMENT COMPOSITION AND (52) U.S. Cl. .......................................................... 424/70.14 HAIR COSMETC FOR DAMAGED HAIR (76) Inventors: Kouhei Hasebe, Gifu (JP); Kikumi (57) ABSTRACT Yamada, Gifu (JP) Correspondence Address: The present invention intends to provide a composition for FRISHAUF, HOLTZ, GOODMAN & CHICK, PC hair treatment containing Y-polyglutamic acid or a salt 220 Fifth Avenue thereof, a hair cosmetic for damaged hair containing Such a 16TH Floor composition, and their uses. The composition for hair treat NEW YORK, NY 10001-7708 (US) ment containing Y-polyglutamic acid or a salt thereof and the hair cosmetic for damaged hair of the present invention have (21) Appl. No.: 10/547,492 excellent improvement effects on the strength and frictional (22) PCT Filed: Mar. 3, 2004 force of hair, so that they can provide tension, elasticity, or the like to damage hair to prevent or alleviate split hair and (86). PCT No.: PCT/PO4/O2606 broken hair as well as improvements in combing and touch. (30) Foreign Application Priority Data Furthermore, they also exert effects of moisture retention inherent to Y-polyglutamic acid or a salt thereof, preventing Mar. 10, 2003 (JP)......................................... 2003-62688 or improving effects on the generation of dandruff on the basis of such effects, preventing effects on the feeling of Publication Classification Stickiness or creak, and various effectiveness including (51) Int. Cl. appropriate residual tendency to hair in a simultaneous A6 IK 8/64 (2006.01) manner, respectively.
    [Show full text]
  • Incorporation of Elastase Inhibitor in Silk Fibroin Nanoparticles for Transdermal Delivery
    Universidade do Minho Escola de Engenharia Ana Vanessa Fernandes Ferreira Incorporation of Elastase Inhibitor in Silk Fibroin Nanoparticles for Transdermal Delivery Incorporation of Elastase Inhibitor in Silk Fibroin DeliveryNanoparticles for Transdermal Ana Vanessa Fernandes Ferreira Fernandes Ana Vanessa Uminho | 2013 Uminho Outubro de 2013 Universidade do Minho Escola de Engenharia Ana Vanessa Fernandes Ferreira Incorporation of Elastase Inhibitor in Silk Fibroin Nanoparticles for Transdermal Delivery Dissertação de Mestrado Mestrado em Bioengenharia Trabalho efetuado sob a orientação do Professor Doutor Artur Cavaco Paulo e coorientação de Doutora Ana Sofia Lemos Machado Abreu Outubro de 2013 DECLARAÇÃO Nome: Ana Vanessa Fernandes Ferreira Endereço eletrónico: [email protected] Título da dissertação: Incorporação de Inibidor de Elastase em Nanopartículas de Fibroína de Seda para Aplicações Transdérmicas (Incorporation of Elastase Inhibitor in Silk Fibroin Nanoparticles for Transdermal Delivery) Orientador (es): Professor Artur Cavaco Paulo e Ana Sofia Lemos Machado Abreu Ano de conclusão: 2013 Designação do Mestrado: Mestrado em Bioengenharia É AUTORIZADA A REPRODUÇÃO INTEGRAL DESTA TESE/TRABALHO APENAS PARA EFEITOS DE INVESTIGAÇÃO, MEDIANTE DECLARAÇÃO ESCRITA DO INTERESSADO, QUE A TAL SE COMPROMETE. Universidade do Minho, 29/11/2013 Assinatura: ____________________________________________________________________________ No amount of experimentation can ever prove me right; a single experiment can prove me wrong. - Albert Einstein To my beloved family Este trabalho não teria sido possível sem a colaboração das pessoas que me ajudaram a concretizá-lo,Agradecimentos tanto a nível profissional / Acknoledgments como pessoal. Agradeço ao meu orientador, Professor Dr. Artur Cavaco Paulo, pela oportunidade de ingressar no seu grupo de trabalho e neste projeto de investigação, por ter confiado e acreditado nas minhas capacidades e potencial, pelo seu apoio e incentivo nestes últimos dois anos.
    [Show full text]
  • Biomolecules of Interest Present in the Main Industrial Wood Species Used in Indonesia-A Review
    Tech Science Press DOI: 10.32604/jrm.2021.014286 REVIEW Biomolecules of Interest Present in the Main Industrial Wood Species Used in Indonesia-A Review Resa Martha1,2, Mahdi Mubarok1,2, Wayan Darmawan2, Wasrin Syafii2, Stéphane Dumarcay1, Christine Gérardin Charbonnier1 and Philippe Gérardin1,* 1Université de Lorraine, Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement, Laboratoire d'Etudes et de Recherche sur le Matériau Bois, Nancy, France 2Department of Forest Products, Faculty of Forestry and Environment, Institut Pertanian Bogor, Bogor University, Bogor, Indonesia *Corresponding Author: Philippe Gérardin. Email: [email protected] Received: 17 September 2020 Accepted: 20 October 2020 ABSTRACT As a tropical archipelagic country, Indonesia’s forests possess high biodiversity, including its wide variety of wood species. Valorisation of biomolecules released from woody plant extracts has been gaining attractive interests since in the middle of 20th century. This paper focuses on a literature review of the potential valorisation of biomole- cules released from twenty wood species exploited in Indonesia. It has revealed that depending on the natural origin of the wood species studied and harmonized with the ethnobotanical and ethnomedicinal knowledge, the extractives derived from the woody plants have given valuable heritages in the fields of medicines and phar- macology. The families of the bioactive compounds found in the extracts mainly consisted of flavonoids, stilbenes, stilbenoids, lignans, tannins, simple phenols, terpenes, terpenoids, alkaloids, quinones, and saponins. In addition, biological or pharmacological activities of the extracts/isolated phytochemicals were recorded to have antioxidant, antimicrobial, antifungal, anti-inflammatory, anti-diabetes, anti-dysentery, anticancer, analgesic, anti-malaria, and anti-Alzheimer activities.
    [Show full text]
  • Dihydromyricetin
    Last updated on May 29, 2020 Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. Dihydromyricetin Evidence Summary DHM has anti-inflammatory, antioxidant, pro-autophagic, and energy metabolism regulating properties due to activation of sirtuins, AMPK, and Nrf2, but poor bioavailability hinders clinical utility. Neuroprotective Benefit: DHM shows anti-inflammatory, antioxidant, and pro-autophagy properties which reduce cognitive impairment in animal models, but a similar level of benefit to humans is unlikely due to low bioavailability. Aging and related health concerns: DHM shows anti-inflammatory and antioxidant properties, and may favorably regulate metabolism by boosting irisin levels, improving insulin sensitivity, and enhancing lipid metabolism in animals; benefits less clear in humans. Safety: DHM has a good safety record in short term RCTs and animal studies, which may be due to low bioavailability. Pharmacokinetic properties may differ across patient populations, and may have drug interactions due to projected CYP inhibition activity. 1 Last updated on May 29, 2020 Availability: OTC Dose: Therapeutic dose not Chemical formula: C15H12O8 established MW: 320.25 g/mol Half-life: 2 hours (in rats) BBB: Penetrant Clinical trials: Type 2 diabetes Observational studies: None (n=77, NAFLD (n=60) Source: PubChem What is it? Dihydromyricetin (DHM), also called ampelopsin, is the major flavonoid in Ampelopsis plants, primarily in the species grossedentata [1].
    [Show full text]
  • Cosmetic Composition Containing Polyorganosiloxane-Containing Epsilon-Polylysine Polymer, and Polyhydric Alcohol, and Production Thereof
    Europäisches Patentamt *EP001604647A1* (19) European Patent Office Office européen des brevets (11) EP 1 604 647 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: A61K 7/48, A61K 7/06, 14.12.2005 Bulletin 2005/50 A61K 7/02, C08G 81/00, C08G 77/452, C08G 77/455, (21) Application number: 05010234.2 C08L 83/10 (22) Date of filing: 11.05.2005 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • Kawasaki, Yuji HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR Ibi-gun Gifu 501-0521 (JP) Designated Extension States: • Hori, Michimasa AL BA HR LV MK YU Gifu-shi Gifu 500-8286 (JP) • Yamamoto, Yuichi (30) Priority: 12.05.2004 JP 2004141778 5-1 Goikaigan Ichiharashi Chiba 290-8551 (JP) • Hiraki, Jun (71) Applicants: Tokyo 104-8555 (JP) • Ichimaru Pharcos Co., Ltd. Motosu-shi, Gifu 501-0475 (JP) (74) Representative: HOFFMANN EITLE • Chisso Corporation Patent- und Rechtsanwälte Osaka-shi, Osaka-fu 530-0005 (JP) Arabellastrasse 4 81925 München (DE) (54) Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof (57) It has been desired to develop a highly preserv- by reducing the amount of antibacterial preservative ative and antibacterial cosmetic composition that can agent to be used. easily be applied to both emulsion and non-emulsion There is provided a cosmetic composition compris- type cosmetics. It has also been desired to develop a ing one or a combination of two or more of polyorganosi- method of improving a preservative and/or antibacterial loxane-containing epsilon-polylysine compounds ob- effect(s) of a cosmetic composition comprising polyor- tained by reacting epsilon-polylysine with polyorganosi- ganosiloxane-containing epsilon-polylysine and there- loxane or a physiologically acceptable salt thereof, and polyhydric alcohol.
    [Show full text]
  • Transnasal Delivery of Fluoxetine HCL to Brain for Treating Depression
    Theranostics of Brain, Spine & Neural Disorders ISSN: 2641-8096 Research Article Theranostics Brain,Spine & Neural Disord Volume 4 Issue 2 - November 2019 Copyright © All rights are reserved by Avinash Ramrao Tekade DOI: 10.19080/JOJS.2019.04.555633 Transnasal Delivery of Fluoxetine HCL to Brain for Treating Depression Sagar Atmaram Aher and Avinash Ramrao Tekade* Department of Pharmaceutics and Pharmaceutical QA, Marathwada MitraMandal’s College of Pharmacy, India Submission: September 17, 2019; Published: November 15, 2019 *Corresponding author: Avinash R Tekade, Department of Pharmaceutics and Pharmaceutical QA, Marathwada Mitra Mandal’s College of Pharmacy, Thergaon, Pune, Maharashtra 411033, India Abstract The objective of this study is to formulate a mucoadhesive microemulsion containing Fluoxetine HCl as antidepressant and Cedar oil as penetration enhancer. Water titration method was used to formulate the microemulsion using two different ratios of selected surfactant and cosurfactant (Tween 80 and Propylene Glycol). The prepared microemulsion showed mean globule size of 303.84nm. The prepared microemulsion ex vivo diffusion is non-irritant for nasal mucosa which was confirmed by ciliotoxicity study using sheep nasal mucosa. It is clearly evident from study that mucoadhesive microemulsion can deliver drug for longer time, the initial release was burst release in the first hour followed by thesustained brain by for nasal next administration.three hours, and increased diffusion will definitely help in reducing dose related side effects
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0209617 A1 Lobisser Et Al
    US 20130209.617A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0209617 A1 Lobisser et al. (43) Pub. Date: Aug. 15, 2013 (54) COMPOSITIONS AND METHODS FOR USE Publication Classification IN PROMOTING PRODUCE HEALTH (51) Int. Cl. (75) Inventors: George Lobisser, Bainbridge Island, A23B 7/16 (2006.01) WA (US); Jason Alexander, Yakima, (52) U.S. Cl. WA (US); Matt Weaver, Selah, WA CPC ........................................ A23B 7/16 (2013.01) (US) USPC ........... 426/102: 426/654; 426/573; 426/601; 426/321 (73) Assignee: PACE INTERNATIONAL, LLC, Seattle, WA (US) (57) ABSTRACT (21) Appl. No.: 13/571,513 Provided herein are compositions comprising one or more of (22) Filed: Aug. 10, 2012 a stilbenoid, stilbenoid derivative, stilbene, or stilbene deriva tive and a produce coating. The resulting compositions are Related U.S. Application Data coatings which promote the health of fruit, vegetables, and/or (60) Provisional application No. 61/522,061, filed on Aug. other plant parts, and/or mitigate decay of post-harvest fruit, 10, 2011. Vegetables, and/or other plant parts. Patent Application Publication Aug. 15, 2013 Sheet 1 of 10 US 2013/0209.617 A1 | s N i has() 3 S s c e (9) SSouffley Patent Application Publication Aug. 15, 2013 Sheet 2 of 10 US 2013/0209.617 A1 so in a N s H N S N N. sr N re C c g o c (saulu) dae. Patent Application Publication Aug. 15, 2013 Sheet 3 of 10 US 2013/0209.617 A1 N Y & | N Y m N 8 Š 8 S.
    [Show full text]
  • Pharmacological Potential of Ampelopsin in Rattan Tea
    Available online at www.sciencedirect.com Food Science and Human Wellness 1 (2012) 14–18 Pharmacological potential of ampelopsin in Rattan tea a a,b,∗ Xianjuan Kou , Ning Chen a College of Health Science, Wuhan Sports University, Wuhan 430079, China b The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA Received 23 July 2012; received in revised form 28 July 2012; accepted 29 August 2012 Abstract Rattan tea, made from the leaves of Ampelopsis grossedentata, may potentially perform multiple pharmacological roles, including anti-bacterial, anti-cancer, antioxidant, hepatoprotective and anti-hypertension functions. These beneficial functions of Rattan tea are strongly associated with the bioactivity of ampelopsin, a major flavonoid compound in Rattan tea. In this review, we summarize current research related to the bioactivity and pharmacological mechanisms of ampelopsin, which will provide a better reference for its potential application in the prevention of chronic diseases. © 2012 Production and hosting by Elsevier B.V. on behalf of Beijing Academy of Food Sciences. Keywords: Ampelopsin; Rattan tea; Flavonoid; Pharmacological potential; Chronic disease 1. Introduction functions and corresponding action mechanisms, as well as potential human health benefits of ampelopsin. Rattan tea is a traditional Chinese herbal remedy prepared from the stems and leaves of the plant Ampelopsis grossedentata. 2. Anti-bacterial and anti-inflammatory effects Ampelopsin is one of the most important flavonoids found in Rattan tea. As a dihydromyricetin (DMY), ampelopsin was first Ampelopsin in crude plant extracts has been applied to alle- isolated from Ampelopsis meliaefolia by Kotake and Kubota in viate inflammatory diseases as a broad-spectrum anti-bacterial 1940, and was later reported as a major bioactive component in drug for several centuries.
    [Show full text]
  • Oral Administration of Ampelopsin Protects Against Acute Brain Injury in Rats Following Focal Cerebral Ischemia
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 13: 1725-1734, 2017 Oral administration of ampelopsin protects against acute brain injury in rats following focal cerebral ischemia XIAO-LI YE1, LING-QUN LU2, WEI LI2, QI LOU2, HONG-GANG GUO2 and QIAO-JUAN SHI2 1Department of Pharmacy, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003; 2Experimental Animal Center, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang 310013, P.R. China Received August 11, 2015; Accepted December 19, 2016 DOI: 10.3892/etm.2017.4197 Abstract. Ampelopsin (AMP) is isolated from the Chinese of the current study indicate a therapeutic role for AMP in the medicinal herb Ampelopsis grossedentata (Hand-Mazz) and treatment of ischemic stroke. has been associated with numerous biological and pharmaco- logical activities. However, it is not clear whether AMP has Introduction a direct protective effect on cerebral ischemia reperfusion injury. Therefore, the present study investigated its role in Stroke is a major life-threatening disease with a worldwide acute brain injury following focal cerebral ischemia in rats. incidence of approximately two in 1,000 per year, and a The current study induced transient focal cerebral ischemia annual 8% mortality rate (1). Despite the development of by performing middle cerebral artery occlusion (MCAO) shock therapy and the application of advanced thrombolytic for 60 min, followed by 24 h of reperfusion. Rats were agents and intravascular procedures, clinical therapy of the exposed to 40, 80 and 160 mg/kg AMP by oral administra- debilitating disorder remains unsatisfactory (2,3). Therefore, tion 30 min prior to MCAO and the cysteinyl leukotriene neuroprophylaxis against stroke has received more attention.
    [Show full text]
  • Benefits of Resveratrol Supplementation
    nutrients Benefits of Resveratrol Supplementation Edited by María P. Portillo and Alfredo Fernández-Quintela Printed Edition of the Special Issue Published in Nutrients www.mdpi.com/journal/nutrients Benefits of Resveratrol Supplementation Benefits of Resveratrol Supplementation Special Issue Editors Mar´ıaP. Portillo Alfredo Fern´andez-Quintela MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade Special Issue Editors Mar´ıa P. Portillo University of the Basque Country (UPV/EHU) Spain Instituto de Salud Carlos III (CIBERobn) Spain Alfredo Fernandez-Quintela´ University of the Basque Country (UPV/EHU) Spain Instituto de Salud Carlos III (CIBERobn) Spain Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Nutrients (ISSN 2072-6643) from 2018 to 2019 (available at: https://www.mdpi.com/journal/nutrients/ special issues/Benefits of Resveratrol Supplementation) For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03921-275-0 (Pbk) ISBN 978-3-03921-276-7 (PDF) c 2019 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND.
    [Show full text]
  • Hovenia Dulcis Thumberg: Phytochemistry, Pharmacology, Toxicology and Regulatory Framework for Its Use in the European Union
    molecules Review Hovenia dulcis Thumberg: Phytochemistry, Pharmacology, Toxicology and Regulatory Framework for Its Use in the European Union Gianluca Sferrazza 1,* , Gloria Brusotti 2,3,* , Manuela Zonfrillo 1, Caterina Temporini 2, Sara Tengattini 2 , Monica Bononi 3,4 , Fernando Tateo 3,4 , Enrica Calleri 2,3 and Pasquale Pierimarchi 1 1 Institute of Translational Pharmacology, National Research Council, Via Fosso del Cavaliere 100, 00133 Rome, Italy; [email protected] (M.Z.); [email protected] (P.P.) 2 Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy; [email protected] (C.T.); [email protected] (S.T.); [email protected] or [email protected] (E.C.) 3 euFAN s.r.l, spin-off University of Pavia, Via Fratelli Cuzio 42, 27100 Pavia, Italy; [email protected] or [email protected] (M.B.); [email protected] or [email protected] (F.T.) 4 Department of Agricultural and Environmental Sciences, University of Milan, Via Celoria 2, 20133 Milan, Italy * Correspondence: [email protected] (G.S.); [email protected] or [email protected] (G.B.) Abstract: Hovenia dulcis Thunberg is an herbal plant, belonging to the Rhamnaceae family, widespread in west Asia, USA, Australia and New Zealand, but still almost unknown in Western countries. H. dulcis has been described to possess several pharmacological properties, such as antidiabetic, Citation: Sferrazza, G.; Brusotti, G.; anticancer, antioxidant, anti-inflammatory and hepatoprotective, especially in the hangover treatment, Zonfrillo, M.; Temporini, C.; validating its use as an herbal remedy in the Chinese Traditional Medicine.
    [Show full text]